120160-29-4

Basic information

• Product Name: 1-(1-Methyl-1H-indol-4-yl)ethanone
• Synonyms: 1-(1-Methyl-1H-indol-4-yl)ethanone
• CAS NO: 120160-29-4
• Molecular Formula: C11H11NO
• Molecular Weight: 173.21114
• Mol File: 120160-29-4.mol

Chemical Properties

• Boiling Point: 320.1±15.0 °C(Predicted)
• Appearance: /
• Density: 1.09±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 1-(1-Methyl-1H-indol-4-yl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1-Methyl-1H-indol-4-yl)ethanone(120160-29-4)
• EPA Substance Registry System: 1-(1-Methyl-1H-indol-4-yl)ethanone(120160-29-4)

Safety Data

• Hazardous Substances Data: 120160-29-4(Hazardous Substances Data)

Usage

Uses

1-(1-Methyl-1H-indol-4-yl)ethanone is used as a psychedelic substance for its entactogenic and hallucinogenic effects. However, it is important to note that 1-(1-Methyl-1H-indol-4-yl)ethanone is not approved for medical use and is classified as an illegal drug in many countries due to its potential for abuse and adverse health effects.

Upstream product

• 50614-86-3 1-(1H-indol-4-yl)ethan-1-one 
• 74-88-4 methyl iodide 
• 590417-55-3 4-bromo-1-methyl-1H-indole 
• 13411-48-8 1-(trimethylsilyl)ethanone 
• 628711-59-1 1-(1-methyl-1H-indol-4-yl)-ethanol 

Relevant articles and documents

Palladium-catalyzed acetylation of arenes

A simple method for the preparation of aryl methyl ketones is reported. The transformation involves the Pd-catalyzed coupling of an acyl anion equivalent, acetyltrimethylsilane, with aryl bromides to afford the corresponding acetylated arenes in synthetically useful yields. The methodology is tolerant of heterocycles and provides a new method for arene functionalization.

10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE

A 10a-azalide compound having a 4-membered ring structure crosslinked at the 10a- and 12-positions, which is represented by the formula (I), and is effective on even Haemophilus influenzae, or erythromycin resistant bacteria (e.g., resistant pneumococci and streptococci).

CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES

The compounds of the invention are represented by the following general structure (I) or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.